Sirnaomics Considers Hong Kong for Ocular Disease Rx Trial, Advances Wound-Healing Program
February 05, 2009
Sirnaomics Considers Hong Kong for Ocular Disease Rx Trial, Advances Wound-Healing Program
A company official said Hong Kong may be the best place to conduct the phase I study since data collected may be used in both US and Chinese regulatory filings.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Sirnaomics Considers Hong Kong for Ocular Rx Trial
February 24, 2009 / Genome Technology - IP Update
April 30, 2009 / Gene Silencing News - Cequent Releases Data on RNAi Technology for Multi-Gene Targeting, Addressing Cancer Drug Resistance
April 23, 2009 / Gene Silencing News - NIH Challenge Grants Offer Opportunities for RNAi, microRNA Researchers
March 19, 2009 / Gene Silencing News - Exiqon Exec Says Impact of miRNA Dx Will Take Time, Company Offers Peek at Other Tests
March 5, 2009 / Gene Silencing News